Literature DB >> 1103555

A controlled study of profylactic long-term treatment of febrile convulsions with phenobarbital.

I Thorn.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1103555     DOI: 10.1111/j.1600-0404.1975.tb01392.x

Source DB:  PubMed          Journal:  Acta Neurol Scand Suppl        ISSN: 0065-1427


× No keyword cloud information.
  9 in total

Review 1.  Disposition of anticonvulsants in childhood.

Authors:  J I Morrow; A Richens
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

2.  Febrile convulsions: intellectual progress in relation to anticonvulsant therapy and to recurrence of fits.

Authors:  J A Smith; S J Wallace
Journal:  Arch Dis Child       Date:  1982-02       Impact factor: 3.791

3.  Prophylaxis and febrile convulsions.

Authors:  D P Addy
Journal:  Arch Dis Child       Date:  1981-02       Impact factor: 3.791

4.  Behavioural effects of phenobarbitone and phenytoin in small children.

Authors:  C J Bacon; J D Cranage; A M Hierons; M D Rawlins; J K Webb
Journal:  Arch Dis Child       Date:  1981-11       Impact factor: 3.791

5.  Phenobarbital for childhood epilepsy: systematic review.

Authors:  Deb K Pal
Journal:  Paediatr Perinat Drug Ther       Date:  2006-05

6.  A clinical trial of single dose rectal and oral administration of diazepam for the prevention of serial seizures in adult epileptic patients.

Authors:  N M Milligan; S Dhillon; A Griffiths; J Oxley; A Richens
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-03       Impact factor: 10.154

7.  Prophylactic diazepam or phenobarbitone in febrile convulsions: a prospective, controlled study.

Authors:  F U Knudsen; S Vestermark
Journal:  Arch Dis Child       Date:  1978-08       Impact factor: 3.791

8.  Sodium valproate versus phenobarbital in the prophylactic treatment of febrile convulsions in childhood.

Authors:  K Lee; J C Melchior
Journal:  Eur J Pediatr       Date:  1981-10       Impact factor: 3.183

Review 9.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.